Copyright: ©Author(s) 2026.
World J Crit Care Med. Jun 9, 2026; 15(2): 118811
Published online Jun 9, 2026. doi: 10.5492/wjccm.v15.i2.118811
Published online Jun 9, 2026. doi: 10.5492/wjccm.v15.i2.118811
Table 3 Studies reporting maximum dosage and duration for different vasopressors, mean ± SD
| Ref. | Year of publication | Studied vasopressor | Study type | Number of patients | Maximum dose studies | Maximum duration (hours) | Complications reported | Rate of complications |
| Cardenas-Garcia et al[9] | 2015 | Noradrenaline | Prospective | 506 | 0.7 ± 0.23 mcg/kg/minute | 49 ± 22 | Extravasation | 16/506 |
| Putland et al[45] | 2006 | Adrenaline | Retrospective | 220 | 1.5 mcg/minute | 19.5 (median) | Extravasation | 11/220 |
| Cardenas-Garcia et al[9] | 2015 | Dopamine | Prospective | 101 | 12.7 mcg/kg/minute | 49 ± 22 | Extravasation | 3/101 |
| Cardenas-Garcia et al[9] | 2015 | Phenylephrine | Prospective | 176 | 3.25 mcg/kg/minute | 49 ± 22 | Extravasation | 0 |
| Lewis et al[10] | 2017 | Vasopressin | Prospective | 4 | 0.04 units/minute | 12.5 | Extravasation | 0 |
- Citation: Singh O, Juneja D. Navigating the veins: A comprehensive review of vasoactive agent infusion via peripheral routes. World J Crit Care Med 2026; 15(2): 118811
- URL: https://www.wjgnet.com/2220-3141/full/v15/i2/118811.htm
- DOI: https://dx.doi.org/10.5492/wjccm.v15.i2.118811